CLSA Lifts Jingfang Pharma Target to HKD61.9 on 24.4% Revenue Growth

Edgen Stock

·Mar 26 2026, 02:40

Share to

Share to

Copy link

Key Takeaways

CLSA raised its target price for Jingfang Pharmaceutical, citing stronger-than-expected financial performance and key advancements in its cancer drug pipeline. The firm maintains an 'Outperform' rating on the stock.

Price Target Increased: CLSA lifted its price target on JINGFANG PHARMACEUTICAL (02595.HK) to HKD61.9 from HKD60.8, signaling renewed confidence.
Revenue Beats Expectations: The company's revenue grew 24.4% year-on-year, and its net loss of RMB1.795 billion was narrower than the market anticipated.
Pipeline Advances: Key drug candidate GFH375 has entered a critical pancreatic cancer registration trial, a significant development milestone.

CLSA Lifts Target to HKD61.9 as Revenue Grows 24.4%

CLSA has increased its price target for JINGFANG PHARMACEUTICAL-B (02595.HK) to HKD61.9 from HKD60.8, maintaining its 'Outperform' rating on the drugmaker. The upgrade comes after the company posted a 24.4% year-on-year increase in revenue, which, along with a net loss of RMB1.795 billion, surpassed market expectations.

Reflecting this positive performance, the investment firm raised its earnings forecasts for Jingfang. It now projects earnings for the current year to be 4% higher and for next year to be 5.3% higher than previously estimated, underscoring a belief in the company's sustained financial execution.

Cancer Drug Pipeline Shows Key Clinical Progress

The optimistic outlook is heavily supported by significant progress in Jingfang's oncology drug pipeline. The company's G12D inhibitor, GFH375, has officially entered the registration trial phase for treating pancreatic cancer, moving it a crucial step closer to potential regulatory approval and commercialization.

Furthermore, the pan-RAS inhibitor GFH276 is identified as a potential long-term growth driver. The drug has demonstrated positive safety signals in its Phase I dose-escalation trial, an essential early milestone in clinical development. This progress positions GFH276 as a promising future asset for the company's portfolio.